More clinical samples, especially more blood samples from HCC patients before and after sorafenib treatment, are required to fully establish the clinical value of targeting circRNA-SORE or YBX1 for overcoming sorafenib resistance in HCC patients. Here, YBX1 is linked to hepatocellular carcinoma.